News

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on multiple sclerosis diets.

A new phase 3 study will explore masitinib's potential as treatment for ALS, aiming to enhance patient outcomes and confirm earlier promising results.

In episode 3, Drs. Olson and Shelgikar break down a retrospective study exploring how social determinants of health impact the clinical experience of patients with narcolepsy. [WATCH TIME: 6 minutes]

Neurology News Network. for the week ending July 26, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 25, 2025.

Panelists Eric Olson, MD, and Anita Shelgikar, MD, examine interim data on high-dose low-sodium oxybate in patients with narcolepsy, discussing safety signals, efficacy trends, and clinical considerations. [WATCH TIME: 4 minutes]

The AHEAD 3-45 Study is currently assessing lecanemab asymptomatic stage of Alzheimer disease to assess whether the therapy can slow biomarker changes or cognitive decline at the earliest phases.

SECA, A randomized clinical trial of 155 patients with chronic subdural hematoma, showed that perioperative continuation of low-dose acetylsalicylic acid did not lower recurrence risk compared with placebo.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with John Sims, MD. [LISTEN TIME: 17 minutes]

AstraZeneca's gefurulimab shows promising results in treating generalized myasthenia gravis, offering patients a convenient, self-administered therapy option.

In this episode, Eric Olson, MD, and Anita Shelgikar, MD, review the XYLO study’s findings on the impact of switching from high- to low-sodium oxybate on blood pressure in patients with narcolepsy.

Findings from a new study from Mayo Clinic may offer clinicians a straightforward metric lesion resolution to aid them in distinguishing MOGAD from MS in routine clinical practice.

A recent study uncovered existing medications that may lower mortality risk in patients with Parkinson disease, suggesting potential for repurposing in future trials.

Helius reported promising results for its Portable Neuromodulation Stimulator, enhancing gait and balance in poststroke patients, with FDA submission planned.

Neurology experts anticipate groundbreaking clinical trial results in 2025, potentially transforming treatment strategies for various neurological conditions.

Apnimed's AD109 shows promising results in treating obstructive sleep apnea, potentially revolutionizing care for millions with a once-daily oral medication.

Findings show that apathy affects more than half of individuals with LBD, challenging assumptions that it emerges only in later stages and underscoring the need for targeted screening tools and intervention strategies.

Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.

The associate professor of neurology at Mayo Clinic Rochester talked about using artificial intelligence-electrocardiogram at baseline to predict adverse vascular events in patients with migraine. [WATCH TIME: 5 minutes]

Findings from a recently published study may offer clinicians a deeper understanding of the complex relationship between Parkinson disease biology and social or environmental factors.

The chief program officer at PMD Alliance described an interactive program designed to help health care providers better understand the lived experience of patients with Parkinson disease and related movement disorders. [WATCH TIME: 6 minutes]

In a new study, findings show elevated CSF 14-3-3 protein levels in AQP4-NMOSD, suggesting its potential as a biomarker for neuroaxonal damage and disease severity.

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]

Navigating insurance hurdles for multiple sclerosis treatments poses significant risks, as seen in a patient's devastating relapse after denied care.

The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]

The FDA-cleared devices allow for a more simplified administration of the liquid medicine Hyqvia, reducing the number of steps needed to prepare for the infusion of 2 dual vial units or more.

New study reveals that alixorexton significantly improves wakefulness and reduces daytime sleepiness in narcolepsy type 1, paving the way for phase 3 trials.

A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigational therapy. [WATCH TIME: 7 minutes]